The disclosure provides new, stable, pharmaceutically acceptable co-crystal forms of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3´ 4´:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.L'invention concerne de nouvelles formes de co-cristaux stables et pharmaceutiquement acceptables de 1-(4-fluoro-phényl)-4-((6bR,10aS)-3-méthyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3'4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, ainsi que des procédés de fabrication et d'utilisation associés, et des compositions pharmaceutiques les comprenant.
